PURPOSE: Changes in DNA methylation of tumor suppressor genes (TSGs) occurring early in carcinogenesis, represent potential indicators for cancer detection and disease evolution.
Our aim was to examine the diagnostic, stratification and prognostic biomarker role of urinary methylation of a novel panel of TSGs in bladder cancer.
MATERIAL AND METHODS: Methylation of 18 TSGs was evaluated in two prospective independent sets of urinary samples (training, n=120; and validation, n=128) from bladder cancer patients (n=170) and controls (n=78) using methylation-specific multiplex ligation-dependent probe amplification assays (MS-MLPA). Diagnostic performance was evaluated using Receiver Operating Curves. Recurrence, progression, and disease-specific survival were analyzed using univariate and multivariate Cox models.
RESULTS: PRDM2, HLTF, ID4, DLC1, BNIP3, H2AFX, CACNA1G, TGIF, and CACNA1A were discovered methylated in bladder cancer. CCND2, SCGB3A1, BNIP3, ID4 and RUNX3 were the most frequently methylated TSGs in both urinary sets. Methylation of several TSGs correlated to clinico-pathologic variables such as stage, tumor grade, focality or age. ROC analyses revealed significant diagnostic accuracies for RUNX3 and CACNA1A in the training set and for RUNX3 and ID4 in the validation set. Using univariate and multivariate analyses, CACNA1A methylation correlated to recurrence in the training set, while in the validation set, PRDM2 significantly associated with recurrence and BNIP3 with disease-specific survival, respectively.
CONCLUSIONS: TSGs methylation allowed histopathologic and clinical stratification. Urinary methylation offered non-invasive utility not only for diagnostic assessment but also as independent prognosticators in bladder cancer.
Written by:
García-Baquero R, Puerta P, Beltran M, Alvarez M, Sacristan R, Alvarez-Ossorio JL, Sánchez-Carbayo M. Are you the author?
Tumor Markers Group, Molecular Pathology Program, Spanish National Cancer Center, Madrid, Spain; Urology Department, Hospital Puerta del Mar, Cadiz, Spain.
Reference: J Urol. 2013 Feb 25. pii: S0022-5347(13)00346-7.
doi: 10.1016/j.juro.2013.01.105
PubMed Abstract
PMID: 23485510
UroToday.com Bladder Cancer Section
